Home/Filings/4/0001641172-25-002927
4//SEC Filing

Bhowmick Neil 4

Accession 0001641172-25-002927

CIK 0001962011other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 8:30 AM ET

Size

5.1 KB

Accession

0001641172-25-002927

Insider Transaction Report

Form 4
Period: 2025-01-01
Bhowmick Neil
Chief Scientific Officer
Transactions
  • Award

    COMMON STOCK

    2025-01-01+14,0001,139,983 total
Footnotes (2)
  • [F1]Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof.
  • [F2]Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting.

Documents

1 file

Issuer

Kairos Pharma, LTD.

CIK 0001962011

Entity typeother

Related Parties

1
  • filerCIK 0001872210

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 8:30 AM ET
Size
5.1 KB